This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
scPharmaceuticals Past Earnings Performance
Past criteria checks 0/6
scPharmaceuticals's earnings have been declining at an average annual rate of -25.8%, while the Pharmaceuticals industry saw earnings growing at 9.8% annually. Revenues have been growing at an average rate of 81.6% per year.
Key information
-25.77%
Earnings growth rate
-8.15%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.95% |
| Revenue growth rate | 81.63% |
| Return on equity | n/a |
| Net Margin | -183.55% |
| Last Earnings Update | 30 Jun 2025 |
Recent past performance updates
Recent updates
Narrative Update • Aug 26
Outpatient Care Shift And Medicare Redesign Will Expand Patient Access
The consensus price target for scPharmaceuticals was raised to $16.75 as analysts reflect the MannKind acquisition at $5.35 per share plus a potential $1.00 CVR, with bullish outlooks on CVR payout likelihood and capped upside from the deal terms. Analyst Commentary Acquisition of scPharmaceuticals by MannKind at $5.35 per share in cash plus a contingent value right (CVR) worth up to $1.00 per share, bringing total potential consideration to $6.35 per share.Analysis Article • Jul 19
scPharmaceuticals Inc. (NASDAQ:SCPH) Soars 26% But It's A Story Of Risk Vs Reward
scPharmaceuticals Inc. ( NASDAQ:SCPH ) shares have continued their recent momentum with a 26% gain in the last month...Analysis Article • Jun 02
Further Upside For scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Could Introduce Price Risks After 40% Bounce
scPharmaceuticals Inc. ( NASDAQ:SCPH ) shares have had a really impressive month, gaining 40% after a shaky period...Analysis Article • May 27
Shareholders Will Likely Find scPharmaceuticals Inc.'s (NASDAQ:SCPH) CEO Compensation Acceptable
Key Insights scPharmaceuticals will host its Annual General Meeting on 3rd of June Salary of US$663.8k is part of CEO...New Narrative • May 13
FDA Approval And Medicare Redesign Will Transform CKD Treatment Access
FDA approval of FUROSCIX for CKD patients significantly expands the market, boosting revenue potential and enhancing growth opportunities.Analysis Article • Apr 04
Market Cool On scPharmaceuticals Inc.'s (NASDAQ:SCPH) Revenues Pushing Shares 30% Lower
scPharmaceuticals Inc. ( NASDAQ:SCPH ) shareholders that were waiting for something to happen have been dealt a blow...Analysis Article • Nov 19
scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless
Unfortunately for some shareholders, the scPharmaceuticals Inc. ( NASDAQ:SCPH ) share price has dived 26% in the last...Analysis Article • Nov 18
Downgrade: Here's How Analysts See scPharmaceuticals Inc. (NASDAQ:SCPH) Performing In The Near Term
Today is shaping up negative for scPharmaceuticals Inc. ( NASDAQ:SCPH ) shareholders, with the analysts delivering a...Analysis Article • Jun 27
Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysis Article • Jun 27
scPharmaceuticals Inc. (NASDAQ:SCPH) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable
scPharmaceuticals Inc. ( NASDAQ:SCPH ) shareholders are no doubt pleased to see that the share price has bounced 26% in...Analysis Article • Mar 16
The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts
scPharmaceuticals Inc. ( NASDAQ:SCPH ) just released its latest full-year results and things are looking bullish. It...Analysis Article • Nov 25
Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Oct 20
scPharmaceuticals: Furoscix Approval A Potential Paradigm Shift For Heart Failure Patients
Summary After two CRLs, FUROSCIX has finally received FDA approval. This treatment could be a game-changer in the treatment of heart failure, allowing certain patients to avoid costly hospitalizations altogether and simply self-administer treatment at home. The stock has been very volatile in the days following approval, but investors should focus on the compelling long-term story. NOTE: For investors new to this stock and the condition of heart failure (“HF”), I encourage you to listen to the Key Opinion Leader (“KOL”) webcast from September 29, 2020. While the physicians that joined President and CEO John Tucker in the webcast— Dr. Nihar Desai (Yale School of Medicine) and Dr. Dan Bensimhon (Cone Health)— are paid consultants of SCPH, it does not invalidate the points they make, nor the validity of the investment opportunity. The slides from the December 3, 2020 Evercore ISI Virtual HealthCONx Conference presentation (download here) are also helpful in understanding the investment thesis (unfortunately, the webcast for this event is not currently active). The majority of the content in this article is supported by what was discussed at these two events. It has been a long wait of 4+ years for investors in scPharmaceuticals (SCPH). The first CRL for lead drug candidate FUROSCIX was received in June 2018, and then a second CRL was received in December 2020. But finally, before the market opened on Monday, October 10, the company announced that FUROSCIX had gotten a thumbs up from the FDA. Though FDA approvals are usually expected to boost the stock price, this stock has been volatile in the days immediately following the approval announcement. On the Monday that the announcement was made, it finished down about 14%, before jumping up over 30% on Tuesday. Other than a possible “buy the rumor, sell the news” explanation, I think the main reason the stock was down on Monday was because of the new $100M debt financing agreement that was announced alongside the FDA approval. However, I think the market overreacted to the news of the new debt facility. If we look at the 2Q22 10-Q filing (pg 10), we can see that the existing “2019 Loan Agreement” was at an interest rate of the higher of (i) LIBOR plus 7.95% or (ii) 10.18% (this loan agreement was for up to $20M, and as of June 30, there was $12.5M drawn, which will be repaid in full using the new debt facility). The new $100M debt agreement with Oaktree Capital Management bears interest at the 3-month secured overnight financing rate (SOFR) plus 8.75%, and the interest rate is capped at 11.75%. Considering the fact that we are in a much higher interest rate environment compared to 2019, the new terms do not seem so unfavorable. The market might also have been disappointed because the new financing agreement confirmed that SCPH will not partner to commercialize FUROSCIX, but instead will commercialize on its own. It always adds an additional risk factor when a biotech that has been specializing in R&D for several years decides to build out its own salesforce rather than partner with an established pharmaceutical company and simply collect a royalty from net sales of its drug. If it goes well for SCPH, then they will end up keeping all of the net sales rather than just a percentage from a licensing agreement. But if it doesn’t go well, it can be an expensive undertaking, as SCPH will bear all of the commercialization costs on its own. This late in the process, however, I don’t think it should come as a surprise that SCPH did not find a partner to market FUROSCIX. Management has made comments during presentations at conferences over the past few years that discussed the salesforce size they thought would be required to reach a majority of the target patients, and I think these statements indicated a likelihood that they would commercialize on their own. What I think is most useful for investors to focus on at this point is not the stock price volatility, but rather the compelling market opportunity for FUROSCIX. 2020 Evercore ISI HealthCONx Conference Presentation 2020 Evercore ISI HealthCONx Conference Presentation Congestive heart failure (also known simply as heart failure) occurs when a patient’s heart is unable to pump blood as forcefully as it should, often causing blood back-ups. Fluid build-up can leak out of blood vessels and swell into other tissues (known as edema, or swelling due to water retention). If there is fluid build-up in the lungs, it can cause shortness of breath and difficulty breathing. Patients can also experience symptoms such as swelling of the belly and overall weight gain. To treat this excess fluid build-up, the medical community has for decades turned to diuretics, which are compounds that increase urine flow. There are three main types of diuretics (loop, thiazide, and potassium-sparing), categorized by their mechanism of action. Of the loop diuretics, furosemide (which goes by the brand name Lasix) is the most commonly prescribed oral and parenteral treatment. At prior events, the SCPH CEO has explained that in the US, there are 6.5M HF patients taking oral Lasix as a maintenance therapy, and that most of them are doing just fine. However, every year, there are approximately 4M instances in which oral Lasix is not enough, as the patients do not see a reduction in swelling in their extremities and body weight. When this occurs, cardiologists tend to double the oral dose, and sometimes even prescribe Zaroxolyn (metolazone), which is a thiazide diuretic. Unfortunately, Zaroxolyn can come with some unfavorable side effects, such as damage to the kidneys. For some patients placed on a new course of treatment, the swelling recedes, and in due time, they can go back to their original oral Lasix maintenance therapy. For patients that do not see a reduction in swelling, their physician will likely decide that they are in need of an even stronger diuretic. This almost always means a treatment of IV Lasix, which requires either a trip to a medical facility or a home visit by a health care practitioner. The benefit that IV Lasix has over oral Lasix, and the reason it is used as a treatment of last resort, is that it offers 100% bioavailability. Bioavailability is simply how much of an administered substance is able to be absorbed by the circulatory system and reach its target area. The higher the bioavailability, the more effective a drug tends to be. This YouTube video (Pharmacology - Loop Diuretics - Furosemide (Lasix) IV in Heart Failure - Dr. Busti) does a good job explaining why oral diuretics are just not enough in certain high-risk HF patients. While I encourage you to watch it in its entirety, if you fast forward to minute 9:00, there is a table that shows the bioavailability of oral Lasix to be only 50%-70% in a normal patient. This means that 30%-50% of the dose never even makes it to its intended targets—and this is in normal patients, with the bioavailability decreasing depending on the health severity of the patient. What investors should take from all of this is that for high-risk HF patients, medical providers cannot take the risk of continuing to go with oral Lasix, and instead need something that guarantees 100% bioavailability. This has always meant IV Lasix—until now. What SCPH has been able to show is that FUROSCIX (a subcutaneous administration of furosemide) is bioequivalent to IV Lasix, in that it offers the same amount of fluid reduction over the course of 6 hours.Seeking Alpha • Oct 10
FDA approves scPharmaceuticals Furoscix to treat congestion in heart failure
The U.S. Food and Drug Administration (FDA) approved scPharmaceuticals (NASDAQ:SCPH) Furoscix's to treat congestion due to fluid overload in adults with New York Heart Association Class 2/3 chronic heart failure. Furoscix, a proprietary formulation of furosemide delivered via an On-Body Infusor, is the first and only FDA-approved subcutaneous loop diuretic which delivers IV equivalent diuresis at home via the Furoscix Infusor, the company said in an Oct. 10 press release. In a study Furoscix showed 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide, scPharmaceuticals noted. Furoscix is not indicated for use in emergency situations or in patients with acute pulmonary edema. The On-Body Infusor will deliver only an 80-mg dose of the drug, the company added. The commercial launch is planned for Q1 2023 by scPharmaceuticals. In a separate release, the company said it signed an agreement for a $100M debt facility. SCPH -6.83% to $4.64 premarketAnalysis Article • Jan 11
Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysis Article • Sep 02
Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Aug 26
scPharmaceuticals: We Still See A High Probability Of Success For FUROSCIX
The FUROSCIX NDA resubmission is expected to occur during 4Q21. Continued data releases demonstrate the cost-reducing value proposition of FUROSCIX. The liquidity position is very favorable.Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How scPharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 25 | 50 | -92 | 85 | 15 |
| 31 Mar 25 | 42 | -91 | 82 | 14 |
| 31 Dec 24 | 36 | -85 | 78 | 12 |
| 30 Sep 24 | 30 | -80 | 73 | 12 |
| 30 Jun 24 | 24 | -61 | 65 | 12 |
| 31 Mar 24 | 18 | -58 | 60 | 12 |
| 31 Dec 23 | 14 | -55 | 53 | 12 |
| 30 Sep 23 | 7 | -50 | 44 | 11 |
| 30 Jun 23 | 4 | -45 | 36 | 11 |
| 31 Mar 23 | 2 | -40 | 29 | 13 |
| 31 Dec 22 | 0 | -37 | 21 | 16 |
| 30 Sep 22 | 0 | -35 | 16 | 18 |
| 30 Jun 22 | 0 | -31 | 12 | 18 |
| 31 Mar 22 | 0 | -29 | 10 | 16 |
| 31 Dec 21 | 0 | -28 | 10 | 16 |
| 30 Sep 21 | 0 | -28 | 11 | 15 |
| 30 Jun 21 | 0 | -31 | 12 | 17 |
| 31 Mar 21 | 0 | -32 | 12 | 18 |
| 31 Dec 20 | 0 | -32 | 12 | 18 |
| 30 Sep 20 | 0 | -35 | 11 | 25 |
| 30 Jun 20 | 0 | -32 | 10 | 25 |
| 31 Mar 20 | 0 | -31 | 9 | 25 |
| 31 Dec 19 | 0 | -33 | 8 | 25 |
| 30 Sep 19 | 0 | -27 | 8 | 17 |
| 30 Jun 19 | 0 | -27 | 8 | 16 |
| 31 Mar 19 | 0 | -29 | 11 | 16 |
| 31 Dec 18 | 0 | -29 | 14 | 16 |
| 30 Sep 18 | 0 | -31 | 15 | 17 |
| 30 Jun 18 | 0 | -31 | 14 | 16 |
| 31 Mar 18 | 0 | -28 | 12 | 15 |
| 31 Dec 17 | 0 | -24 | 9 | 14 |
| 30 Sep 17 | 0 | -22 | 7 | 14 |
| 30 Jun 17 | 0 | -26 | 8 | 14 |
| 31 Mar 17 | 0 | -24 | 7 | 12 |
| 31 Dec 16 | 0 | -24 | 6 | 12 |
Quality Earnings: SCPH is currently unprofitable.
Growing Profit Margin: SCPH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SCPH is unprofitable, and losses have increased over the past 5 years at a rate of 25.8% per year.
Accelerating Growth: Unable to compare SCPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SCPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.4%).
Return on Equity
High ROE: SCPH's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/08 20:50 |
| End of Day Share Price | 2025/10/06 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
scPharmaceuticals Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | BMO Capital Markets Equity Research |
| Gary Nachman | BMO Capital Markets Equity Research |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |